Company news

AnaptysBio, Inc. news in 2024

AnaptysBio, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis

December 10, 2024

Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update

November 4, 2024

Anaptys Announces Participation in November and December Investor Conferences

November 4, 2024

Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering

August 13, 2024

Anaptys Announces Second Quarter 2024 Financial Results and Provides Business Update

August 4, 2024

Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sagard in Exchange for Additional Jemperli Royalties

May 8, 2024

Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)

May 8, 2024

Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update

May 8, 2024

Actym Therapeutics Appoints Thomas Smart as CEO

April 23, 2024

Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

March 10, 2024

Anaptys to Present at TD Cowen’s 44th Annual Health Care Conference and 2024 AAD Annual Meeting

February 28, 2024

Anaptys to Present at Guggenheim’s 6th Annual Biotechnology Conference

January 30, 2024

Decks in 2024